Phosphodiesterase inhibition to target the synaptic dysfunction in alzheimer's disease

Topics in Medicinal Chemistry

Volumn 6, Issue , 2010, Pages 57-90

  Bales, Kelly R ^a   Plath, Niels ^b   Svenstrup, Niels ^b   Menniti, Frank S ^c  

^a PFIZER INC   (United States)

^b H LUNDBECK A S   (Denmark)

^c Mnemosyne Pharmaceuticals Inc   (United States)

Author keywords

Alzheimer's disease; Cyclic nucleotide; PDE2A; PDE4; PDE5A; PDE7; PDE8B; PDE9A; Phosphodiesterase; Synaptic plasticity

Indexed keywords

EID: 84866247267     PISSN: 18622461     EISSN: 1862247X     Source Type: Book Series    
DOI: 10.1007/7355-2010-8     Document Type: Article

References (156)

1. Gauthier S, Reisberg B, Zaudig M et al. (2006) Mild cognitive impairment. Lancet 367: 1262-1270
2. Cummings JL (2004) Alzheimer's disease. N Engl J Med 351:56-67
3. Francis PT, Palmer AM, Snape M et al. (1999) The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 66:137-147
4. Reisberg B, Doody R, Stoffler A et al. (2003) Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348:1333-1341
5. Chartier-Harlin MC, Crawford F, Houlden H et al. (1991) Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 353:844-846
6. Murrell J, Farlow M, Ghetti B et al. (1991) A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 254:97-99
7. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298:789-791
8. Roberts GW, Nash M, Ince PG et al. (1993) On the origin of Alzheimer's disease: a hypothesis. Neuroreport 4:7-9
9. Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76: 481-511
10. Terry R, Masliah E, Salmon D et al. (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572-580
11. Scheff S, Price D (2003) Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol Aging 24:1029-1046
12. Masliah E, Mallory M, Alford M et al. (2001) Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 56:127-129
13. Masliah E, Mallory M, Alford M et al. (1994) Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci Lett 174:67-72
14. Mirra SS, Heyman A, McKeel D et al. (1991) The consortium to establish a registry for Alzheimer's disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41:479
15. Braak H, Braak E (1995) Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 16:271-278
16. Braak H, Alafuzo I, Arzberger T et al. (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using parafin sections and immunocytochemistry. Acta Neuropathol 112:389-404
17. Small DH, Mok SS, Bornstein JC (2001) Alzheimer's disease and Ab toxicity: from top to bottom. Nat Rev Neurosci 2:595-598
18. Samir K-S, Jessie T, Van Bianca B et al. (2006) Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased Ab42 and decreased Ab40. Hum Mutat 27:686-695
19. Hardy J, Higgins G (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256:184-185
20. Rowe CC, Ng S, Ackermann U et al. (2007) Imaging beta-amyloid burden in aging and dementia. Neurology 68:1718-1725
21. Mufson E, Chen E-Y, Cochran E et al. (1999) Entorhinal cortex b-amyloid load in individuals with mild cognitive impairment. Exp Neurol 158:469-490
22. Hyman BT, Van Hoesen GW, Damasio AR et al. (1984) Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 225:1168-1170
23. Lue L-F, Kuo Y-M, Roher AE et al. (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155:853-862
24. Zheng H, Koo E (2006) The amyloid precursor protein: beyond amyloid. Mol Neurodegener 1:5
25. Tampellini D, Rahman N, Gallo EF et al. (2009) Synaptic activity reduces intraneuronal Abeta, promotes app transport to synapses, and protects against Abeta-related synaptic alterations. J Neurosci 29:9704-9713
26. Cirrito J, Yamada K, Finn M et al. (2005) Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48:913-922
27. Calabrese B, Shaked G, Tabarean I et al. (2007) Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-beta protein. Mol Cell Neurosci 35:183-193
28. Shrestha B, Vitolo O, Joshi P et al. (2006) Amyloid beta peptide adversely affects spine number and motility in hippocampal neurons. Mol Cell Neurosci 33:274-282
29. Cleary JP, Walsh DM, Hofmeister JJ et al. (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8:79-84
30. Arancio O, Puzzo D, Privitera L et al. (2008) Amyloid-beta peptide is a positive modulator of synaptic plasticity and memory. Alzheimers Dement 4:T196-T197
31. Giuffrida ML, Caraci F, Pignataro B et al. (2009) b-amyloid monomers are neuroprotective. J Neurosci 29:10582-10587
32. Corder E, Saunders A, StrittmatterWet al (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923
33. Farrer L, Cupples L, Haines J et al. (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. ApoE and Alzheimer disease meta analysis consortium. JAMA 278:1349-1356
34. Corder EH, Saunders AM, Risch NJ et al. (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 7:180-184
35. Deary IJ, Whiteman MC, Pattie A et al. (2002) Ageing: cognitive change and the APOE epsilon 4 allele. Nature 418:932
36. Filippini N, MacIntosh BJ, Hough MG et al. (2009) Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad Sci USA 106:7209-7214
37. Reiman EM, Chen K, Alexander GE et al. (2005) Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci USA 102:8299-8302
38. Busch RM, Lineweaver TT, Naugle RI et al. (2007) Apoe-epsilon4 is associated with reduced memory in long-standing intractable temporal lobe epilepsy. Neurology 68:409-414
39. Palop JJ, Chin J, Roberson ED et al. (2007) Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55:697-711
40. Ponomareva NV, Korovaitseva GI, Rogaev EI (2008) EEG alterations in non-demented individuals related to apolipoprotein E genotype and to risk of Alzheimer disease. Neurobiol Aging 29:819-827
41. Ponomareva NV, Selesneva ND, Jarikov GA (2003) EEG alterations in subjects at high familial risk for Alzheimer's disease. Neuropsychobiology 48:152-159
42. Wang C, Wilson W, Moore S et al. (2005) Human APOE4-targeted replacement mice display synaptic deficits in the absence of neuropathology. Neurobiol Dis 18:390-398
43. Francis S, Corbin J (1999) Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. Crit Rev Clin Lab Sci 36:275-328
44. Kaupp UB, Seifert R (2002) Cyclic nucleotide-gated ion channels. Physiol Rev 82: 769-824
45. Bos JL (2006) Epac proteins: multi-purpose cAMP targets. Trends Biochem Sci 31: 680-686
46. Malenka RC, Bear MF (2004) LTP and Ltd: an embarrassment of riches. Neuron 44:5-21
47. Citri A, Malenka RC (2008) Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacol 33:18-41
48. Kandel E (2001) The molecular biology of memory storage: a dialogue between genes and synapses. Science 294:1030-1038
49. Abel T, Nguyen P, Barad M et al. (1997) Genetic demonstration of a role for PKA in the late phase of LTP and in hippocampus-based long-term memory. Cell 88:615-626
50. Lisman J (1989) A mechanism for the Hebb and the anti-Hebb processes underlying learning and memory. Proc Natl Acad Sci USA 86:9574-9578
51. Esteban J, Shi S, Wilson C et al. (2003) PKA phosphorylation of AMPA receptor subunits controls synaptic trafficking underlying plasticity. Nat Neurosci 6:136-143
52. Banke T, Bowie D, Lee H et al. (2000) Control of GluR1 AMPA receptor function by cAMP dependent protein kinase. J Neurosci 20:89-102
53. Lysetskiy M, Foldy C, Soltesz I (2005) Long- and short-term plasticity at mossy fiber synapses on mossy cells in the rat dentate gyrus. Hippocampus 15:691-696
54. Weisskopf M, Castillo P, Zalutsky R et al. (1994) Mediation of hippocampal mossy fiber long-term potentiation by cyclic AMP. Science 265:1878-1882
55. Nicoll R, Schmitz D (2005) Synaptic plasticity at hippocampal mossy fibre synapses. Nat Rev Neurosci 6:863-876
56. Kemp A, Manahan-Vaughan D (2007) Hippocampal long-term depression: master or minion in declarative memory processes? Trends Neurosci 30:111-118
57. Bear MF, Abraham WC (1996) Long-term depression in hippocampus. Annu Rev Neurosci 19:437-462
58. Lee H, Barbarosie M, Kameyama K et al. (2000) Regulation of distinct ampa receptor phosphorylation sites during bidirectional synaptic plasticity. Nature 405:955-959
59. Kleppisch T, Feil R (2009) Cgmp signalling in the mammalian brain: role in synaptic plasticity and behaviour. In: Schmidt H, Stasch J-P, Hofmann F (eds) CGMP: generators, effectors and therapeutic implications. Springer, Berlin, pp 549-579
60. Hawkins R, Son H, Arancio O (1998) Nitric oxide as a retrograde messenger during longterm potentiation in hippocampus. Prog Brain Res 118:155-172
61. Arancio O, Kandel E, Hawkins R (1995) Activity-dependent long-term enhancement of transmitter release by presynaptic 3', 5'-cyclic GMP in cultured hippocampal neurons. Nature 376:74-80
62. Arancio O, Kiebler M, Lee C et al. (1996) Nitric oxide acts directly in the presynaptic neuron to produce long-term potentiation in cultured hippocampal neurons. Cell 87:1025-1035
63. Son H, Lu Y-F, Zhuo M et al. (1998) The specific role of cGMP in hippocampal LTP. Learn Mem 5:231-245
64. Lu Y-F, Kandel ER, Hawkins RD (1999) Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J Neurosci 19:10250-10261
65. Haghikia A, Mergia E, Friebe A et al. (2007) Long-term potentiation in the visual cortex requires both nitric oxide receptor guanylyl cyclases. J Neurosci 27:818-823
66. Hopper RA, Garthwaite J (2006) Tonic and phasic nitric oxide signals in hippocampal longterm potentiation. J Neurosci 26:11513-11521
67. Zhuo M, Kandel E, Hawkins R (1994) Nitric oxide and cGMP can produce either synaptic depression or potentiation depending on the frequency of presynaptic stimulation in hippocampus. Neuroreport 5:1033-1036
68. Reyes-Harde M, Potter BVL, Galione A et al. (1999) Induction of hippocampal LTD requires nitric-oxide-stimulated PKG activity and ca2+ release from cyclic ADP-ribose-sensitive stores. J Neurophysiol 82:1569-1576
69. Wei J, Jin X, Cohen E et al. (2002) cGMP-induced presynaptic depression and postsynaptic facilitation at glutamatergic synapses in visual cortex. Brain Res 927:42-54
70. Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109:366-398
71. Ke H, Wang H (2006) Structure, catalytic mechanism, and inhibitor selectivity of cyclic nucleotide phosphodiesterases. In: Beavo JA, Francis SH, Houslay MD (eds) Cyclic nucleotide phosphodiesterases in health and disease. CRC, Boca Raton, FL
72. Scapin G, Patel SB, Chung C et al. (2004) Crystal structure of human phosphodiesterase 3b: atomic basis for substrate and inhibitor specificity. Biochemistry 43:6091-6100
73. Ke H, Wang H (2007) Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity. Curr Top Med Chem 7:391-403
74. Wang H, Yan Z, Yang S et al. (2008) Kinetic and structural studies of phosphodiesterase-8a and implication on the inhibitor selectivity. Biochemistry 47:12760-12768
75. Verhoest PR, Chapin DS, Corman M et al. (2009) Discovery of a novel class of phosphodiesterase 10a inhibitors and identification of clinical candidate 2-[4-(1-methyl- 4-pyridin-4-yl-1 h-pyrazol-3-yl)-phenoxymethyl]-quinoline (pf-2545920) for the treatment of schizophrenia. J Med Chem 52:7946-7949
76. Wang H, Liu Y, Hou J et al. (2007) Structural insight into substrate specificity of phosphodiesterase, Proc Natl Acad Sci 104:5782-5787
77. Zhang KYJ, Card GL, Suzuki Y et al. (2004) A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol Cell 15:279-286
78. Liu S, Mansour MN, Dillman KS et al. (2008) Structural basis for the catalytic mechanism of human phosphodiesterase 9. Proc Natl Acad Sci 105:13309-13314
79. Zoraghi R, Corbin JD, Francis SH (2006) Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity. J Biol Chem 281:5553-5558
80. Sandner P, Svenstrup N, Tinel H et al. (2008) Phosphodiesterase 5 inhibitors and erectile dysfunction. Expert Opin Ther Pat 18:21-33
81. Sung BJ, Hwang KY, Jeon YH et al. (2003) Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature 425:98-102
82. Smith FD, Scott JD (2006) Anchored cAMP signaling: onward and upward - a short history of compartmentalized cAMP signal transduction. Eur J Cell Biol 85:585-592
83. Baillie G, Scott J, Houslay M (2005) Compartmentalisation of phosphodiesterases and protein kinase a: opposites attract. FEBS Lett 579:3264-3270
84. Houslay MD, Adams DR (2003) PDE4 cAMP phosphodiesterasesmodular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370:1-18
85. Jin SLC, Lan L, Zoudilova M et al. (2005) Specific role of phosphodiesterase 4b in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol 175:1523-1531
86. Menniti FS, Faraci WS, Schmidt CJ (2006) Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 5:660-670
87. Rose G, Hopper A, De Vivo M et al. (2005) Phosphodiesterase inhibitors for cognitive enhancement. Curr Pharm Des 11:3329-3334
88. Barad M, Bourtchouladze R, Winder DG et al. (1998) Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc Natl Acad Sci USA 95:15020-15025
89. Reneerkens O, Rutten K, Steinbusch H et al. (2009) Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacol 202:419-443
90. Gong B, Vitolo O, Trinchese F et al. (2004) Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 114:1624-1634
91. Cullen W, Suh Y, Anwyl R et al. (1997) Block of LTP in rat hippocampus in vivo by betaamyloid precursor protein fragments. Neuroreport 8:3213-3217
92. Itoh A (1999) Impairments of long-term potentiation in hippocampal slices of beta-amyloid infused rats. Eur J Pharmacol 382:167-175
93. Vitolo O (2002) Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci USA 99:13217-13221
94. Giembycz MA (2009) Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol 155:228-290
95. Sturton G, Fitzgerald M (2002) Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest 121:192S-196S
96. Rutten K, Basile JL, Prickaerts J et al. (2008) Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques. Psychopharmacology (Berl) 196:643-648
97. Ramos BP, Birnbaum SG, Lindenmayer I et al. (2003) Dysregulation of protein kinase a signaling in the aged prefrontal cortex: new strategy for treating age-related cognitive decline. Neuron 40:835-845
98. Cherry JA, Davis RL (1999) Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J Comp Neurol 407:287-301
99. Rutten K, Misner D, Works M et al. (2008) Enhanced long-term potentiation and impaired learning in phosphodiesterase 4d-knockout (PDE4d) mice. Eur J Neurosci 28:625-632
100. Ahmed T, Frey J (2005) Phosphodiesterase 4b (PDE4b) and cAMP-level regulation within different tissue fractions of rat hippocampal slices during long-term potentiation in vitro. Brain Res 1041:212-222
101. Millar JK, Pickard BS, Mackie S et al. (2005) DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 310:1187-1191
102. Fatemi S, King D, Reutiman T et al. (2008) PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia. Schizophr Res 101:36-49
103. Numata S, Ueno S, Iga J et al. (2008) Positive association of the PDE4B (phosphodiesterase 4B) gene with schizophrenia in the japanese population. J Psychiatr Res 43:7-12
104. Robichaud A, Stamatiou P, Jin S et al. (2002) Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 110:1045-1052
105. Chambers R, Abrams K, Castleberry T et al. (2006) A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function. Bioorg Med Chem Lett 16:718-721
106. Kranz M, Wall M, Evans B et al. (2009) Identification of PDE4B over 4D subtype-selective inhibitors revealing an unprecedented binding mode. Bioorg Med Chem 17:5336-5341
107. Naganuma K, Omura A, Maekawara N et al. (2009) Discovery of selective PDE4B inhibitors. Bioorg Med Chem Lett 19:3174-3176
108. Giembycz MA, Smith SJ (2006) Phosphodiesterase 7 (PDE7) as a therapeutic target. Drugs Future 31:207-229
109. Michaeli T (2006) Pde7. In: Beavo JA, Francis SH, Houslay MD (eds) Cyclic nucleotide phosphodiesterases in health and disease. CRC, Boca Raton, FL, pp 195-204
110. Han P, Sonati P, Rubin C et al. (2006) Pde7a1, a camp-specific phosphodiesterase, inhibits camp-dependent protein kinase by a direct interaction with c. J Biol Chem 281:15050-15057
111. Gil C, Campillo NE, Perez DI et al. (2008) PDE7 inhibitors as new drugs for neurological and inflammatory disorders. Expert Opin Ther Pat 18:1127-1139
112. Bergmann JE, Cutshall NS, Demopulos GA et al. (2008) Use of PDE7 inhibitors for the treatment of movement disorders, US 20080260643
113. Vasta V (2006) cAMP-phosphodiesterase 8 family. In: Beavo JA, Francis SH, Houslay MD (eds) Cyclic nucleotide phosphodiesterases in health and disease. CRC, Boca Raton, FL
114. Sandner P, Hutter J, Tinel H et al. (2007) PDE5 inhibitors beyond erectile dysfunction. Int J Impot Res 19:533-543
115. Prickaerts J, Sik A, van Staveren W et al. (2004) Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. Neurochem Int 45:915-928
116. Rutten K, Prickaerts J, Hendrix M et al. (2007) Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. Eur J Pharmacol 558:107-112
117. Devan B, Duffy K, Bowker J et al. (2005) Phosphodiesterase type 5 (PDE5) inhibition and cognitive enhancement. Drugs Future 30:725
118. Goff D, Cather C, Freudenreich O et al. (2009) A placebo-controlled study of sildenafil effects on cognition in schizophrenia. Psychopharmacol 202:411-417
119. Menniti F, Ren J, Coskran T et al. (2009) PDE5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen and implications for mechanism. J Pharmacol Exp Ther 331:1-9
120. Zhang L, Zhang RL, Wang Y et al. (2005) Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor. Stroke 36:847-852
121. Zhang L, Zhang Z, Zhang RL et al. (2006) Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke. Brain Res 1118:192-198
122. Zhang R, Wang Y, Zhang L et al. (2002) Sildenafil (viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 33:2675-2680
123. Puzzo D, Staniszewski A, Deng SX et al. (2009) Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model. J Neurosci 29:8075-8086
124. Van Staveren W, Steinbusch H, Markerink-Van Ittersum M et al. (2003) Mrna expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J Comp Neurol 467:566-580
125. Kotera J, Fujishige K, Omori K (2000) Immunohistochemical localization of cGMPbinding cGMP-specific phosphodiesterase (PDE5) in rat tissues. J Histochem Cytochem 48:685-694
126. Reyes-Irisarri E, Markerink-Van Ittersum M, Mengod G et al. (2007) Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains. Eur J Neurosci 25:3332-3338
127. Kruse LS, Sandholdt NTH, Gammeltoft S et al. (2006) Phosphodiesterase 3 and 5 and cyclic nucleotide-gated ion channel expression in rat trigeminovascular system. Neurosci Lett 404:202-207
128. Andreeva S, Dikkes P, Epstein P et al. (2001) Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain. J Neurosci 21:9068-9076
129. Guipponi M, Scott HS, Kudoh J et al. (1998) Identification and characterization of a novel cyclic nucleotide phosphodiesterase gene (PDE9A) that maps to 21q22.3: alternative splicing of mRNA transcripts, genomic structure and sequence. Hum Genet 103:386-392
130. Rentero C, Monfort A, Puigdomenech P (2003) Identification and distribution of different mRNA variants produced by differential splicing in the human phosphodiesterase 9A gene. Biochem Biophys Res Commun 301:686-692
131. Wang P, Wu P, Egan RW et al. (2003) Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5). Differential tissue distribution and subcellular localization of PDE9A variants. Gene 314:15-27
132. Fisher DA, Smith JF, Pillar JS et al. (1998) Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 273:15559-15564
133. Soderling SH, Bayuga SJ, Beavo JA (1998) Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 273:15553-15558
134. Kruse LS, Moller M, TibaekMet al (2009) PDE9A, PDE10A, and PDE11A expression in rat trigeminovascular pain signalling system. Brain Res 1281:25-34
135. Wunder F, Tersteegen A, Rebmann A et al. (2005) Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol Pharmacol 68:1775-1781
136. van der Staay F, Rutten K, Barfacker L et al. (2008) The novel selective PDE9 inhibitor bay 73-6691 improves learning and memory in rodents. Neuropharmacol 55:908-918
137. Menniti FS, Kleiman R, Schmidt C (2008) PDE9A-mediated regulation of cGMP: impact on synaptic plasticity. Schizophr Res 102:38-39
138. Schmidt CJ, Harms JF, Tingley FD et al. (2009) PDE9A-mediated regulation of cGMP: developing a biomarker for a novel therapy for Alzheimer's disease. Alzheimers Dement 5: P331
139. Nicholas T, Evans R, Styren S et al. (2009) Pf-04447943, a novel PDE9A inhibitor, increases cGMP levels in cerebrospinal fluid: translation from non-clinical species to healthy human volunteers. Alzheimers Dement 5:P330-P331
140. Kubinyi H, Muller G (eds) (2004) Chemogenomics in drug discovery: a medicinal chemistry perspective. Wiley-VCH, Weinheim
141. Huai Q, Wang H, Zhang W et al. (2004) Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding. Proc Natl Acad Sci USA 101:9624-9629
142. Wang H, Ye M, Robinson H et al. (2008) Conformational variations of both phosphodiesterase- 5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Mol Pharmacol 73:104-110
143. Deninno MP, Andrews M, Bell AS et al. (2009) The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. Bioorg Med Chem Lett 19:2537-2541
144. Stroop S, Beavo J (1991) Structure and function studies of the cGMP-stimulated phosphodiesterase. J Biol Chem 266:23802-23809
145. Rosman GJ, Martins TJ, Sonnenburg WK et al. (1997) Isolation and characterization of human cDNAs encoding a cGMP-stimulated 30, 50-cyclic nucleotide phosphodiesterase. Gene 191:89-95
146. Sonnenburg WK, Mullaney PJ, Beavo JA (1991) Molecular cloning of a cyclic GMPstimulated cyclic nucleotide phosphodiesterase cDNA. Identification and distribution of isozyme variants. J Biol Chem 266:17655-17661
147. Yang Q, Paskind M, Bolger G et al. (1994) A novel cyclic GMP stimulated phosphodiesterase from rat brain. Biochem Biophys Res Commun 205:1850-1858
148. Russwurm C, Zoidl G, Koesling D et al. (2009) Dual acylation of PDE2A splice variant 3: targeting to synaptic membranes. J Biol Chem 284:25782-25790
149. Noyama K, Maekawa S (2003) Localization of cyclic nucleotide phosphodiesterase 2 in the brain-derived triton-insoluble low-density fraction (raft). Neurosci Res 45:141-148
150. Suvarna NU, O'Donnell JM (2002) Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus. J Pharmacol Exp Ther 302:249-256
151. Sadhu K, Hensley K, Florio VA et al. (1999) Differential expression of the cyclic GMPstimulated phosphodiesterase PDE2A in human venous and capillary endothelial cells. J Histochem Cytochem 47:895-906
152. Stephenson DT, Coskran TM, Wilhelms MB et al. (2009) Immunohistochemical localization of PDE2A in multiple mammalian species. J Histochem Cytochem 57:933-949
153. Boess F, Hendrix M, van der Staay F et al. (2004) Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacol 47:1081-1092
154. Domek-Lopacinska K, Strosznajder JB (2008) The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Res 1216:68-77
155. Bender A (2006) Calmodulin-stimulated cycli nucleotide phosphodiesterease. In: Beavo JA, Francis SH, Houslay MD (eds) Cyclic nucleotide phosphodiesterases in health and disease. CRC, Boca Raton, FL, pp 35-54
156. Podzuweit T, Nennstiel P, Muller A (1995) Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3- nonyl) adenine. Cell Signal 7:733-738